Cargando…
What Are the Reasons for Continuing Failures in Cancer Therapy? Are Misleading/Inappropriate Preclinical Assays to Be Blamed? Might Some Modern Therapies Cause More Harm than Benefit?
Over 50 years of cancer research has resulted in the generation of massive amounts of information, but relatively little progress has been made in the treatment of patients with solid tumors, except for extending their survival for a few months at best. Here, we will briefly discuss some of the reas...
Autores principales: | Mirzayans, Razmik, Murray, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655591/ https://www.ncbi.nlm.nih.gov/pubmed/36362004 http://dx.doi.org/10.3390/ijms232113217 |
Ejemplares similares
-
Do TUNEL and Other Apoptosis Assays Detect Cell Death in Preclinical Studies?
por: Mirzayans, Razmik, et al.
Publicado: (2020) -
You might as well smoke; the misleading and harmful public message about smokeless tobacco
por: Phillips, Carl V, et al.
Publicado: (2005) -
Cellular Responses to Platinum-Based Anticancer Drugs and UVC: Role of p53 and Implications for Cancer Therapy
por: Murray, David, et al.
Publicado: (2020) -
Intratumor Heterogeneity and Therapy Resistance: Contributions of Dormancy, Apoptosis Reversal (Anastasis) and Cell Fusion to Disease Recurrence
por: Mirzayans, Razmik, et al.
Publicado: (2020) -
The Cellular Response to DNA Damage: From DNA Repair to Polyploidy and Beyond
por: Mirzayans, Razmik
Publicado: (2023)